Joseph P. Hagan - Jan 30, 2025 Form 4 Insider Report for Regulus Therapeutics Inc. (RGLS)

Role
Chief Executive Officer, Director
Signature
Christopher Aker, Attorney in Fact
Stock symbol
RGLS
Transactions as of
Jan 30, 2025
Transactions value $
$54,260
Form type
4
Date filed
1/31/2025, 05:00 PM
Previous filing
Jan 15, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGLS Common Stock Purchase $54.3K +50K +23.72% $1.09 261K Jan 30, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGLS Stock Option (Right to Buy) Award $0 +1.35M $0.00 1.35M Jan 30, 2025 Common Stock 1.35M $1.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The weighted average purchase price for the transaction reported was $1.0852, and the range of prices were between $1.065 and $1.0897. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each price will be provided.
F2 The stock option commenced vesting on January 1, 2025 and will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date.